Evolution of therapies for myelofibrosis (MF): From palliation to disease modification

Myelofibrosis (MF), a form of myeloproliferative neoplasm (MPN), is a rare cancer where the bone marrow makes too many of one kind of blood cell. In MF, the abnormal cells cause normal bone marrow to be replaced by scar tissue. Over time, the fibrous scar tissue makes it harder for the bone marrow to produce normal blood cells. Fortunately, research into NMPs has meant that we are seeing an evolution in treatments and management.

In this 1-hour live webcast, Dr. Vikas Gupta, Hematologist at the Princess Margaret Cancer Centre inToronto, will review MF and the evolution in diagnosis, treatment options and aspects of follow-up care.

Dr. Vikas Gupta

Dr. Gupta is multidisciplinary clinical lead of the Leukemia Program at Princess Margaret Cancer Centre, and Director of the Elizabeth and Tony Comper MPN program. He holds the Barbara Baker Chair in Leukemia and Related Disorders at the University Health Network. His clinical and research activities are focused on developing novel transplant and non-transplant-based treatment strategies for patients with myeloproliferative neoplasms (MPN). He is the founding member and past president of the Canadian MPN Group. The MPN program at the Princess Margaret acts as a national resource for the care of complex patients with MPN. The MPN program offers short and long-term skills building opportunities for fellowship training, training of community hematologists/oncologists and other health care providers.